Recursion Pharmaceuticals Inc - Ordinary Shares - Class A
RXRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.61B
Close$
Share Statistics
| Market cap | $1.61 Billion |
|---|---|
| Enterprise Value | $1.06 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.44 |
| Beta | 1.05 |
| Outstanding Shares | 529,303,984 |
Return
| Return on Equity | -54.62% |
|---|---|
| Return on Assets | -41.79% |
| Return on Invested Capital | -49.59% |
Valuation & Multiples
| P/E Ratio | -3.39 |
|---|---|
| PEG | 8.09 |
| Price to Sales | - |
| Price to Book Ratio | 3.47 |
| Enterprise Value to Revenue | 15.93 |
| Enterprise Value to EBIT | -1.76 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.25
Average shareholder expectationRevenue Estimate
$17.46 M
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.26
Average shareholder expectationRevenue Estimate
$12.12 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6416▼ 15.49% |
|---|---|
| Total Calls | 4,595,352▼ 37.69% |
| Total Puts | 2,948,200▼ 49.81% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 75.12%▲ 2.58% |
|---|---|
| Total Invested | $1.03B▼ 22.18% |
| Investors Holding | 349▲ 2.00% |
ESG Score
No data
About Recursion Pharmaceuticals Inc
218 employeesRecursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patient...